Download Shotsy on the App Store Download Shotsy on the Play Store

GLP‑1 and hydration: how much water you really need

GLP‑1 medications increase your risk of dehydration because you eat less food, experience GI side effects, and may not feel as thirsty. Here is how much water you actually need and how to stay on top of it.

Read More →

GLP‑1 and mental health: mood changes, anxiety, and what the research says

Some GLP‑1 users report mood changes and anxiety, while others feel better than ever. Here's what the research says about GLP‑1 medications and mental health, including what regulators found and when to talk to your doctor.

Read More →

GLP‑1 and heart health: the cardiovascular benefits explained

GLP‑1 medications do more than help with weight loss. Landmark trials show semaglutide reduces major cardiovascular events by 20%, earning Wegovy an FDA approval for heart risk reduction. Here's what the research says.

Read More →

How to give yourself a GLP‑1 injection: a step-by-step guide

Nervous about your first GLP‑1 injection? All injectable GLP‑1 medications use pre-filled auto-injector pens that make the process simple. Here's a complete step-by-step guide to injecting safely and comfortably.

Read More →

What to do if you miss a GLP‑1 dose: medication-by-medication guide

Missing a GLP‑1 dose doesn't have to derail your progress. Here's exactly when to take a late dose vs. skip it entirely for every major GLP‑1 medication, plus how to prevent missed doses in the future.

Read More →

GLP‑1 and acid reflux: managing heartburn and GERD on treatment

Acid reflux and GERD affect 9 to 15 percent of GLP‑1 users in clinical trials, driven by delayed gastric emptying. Learn why it happens, what makes it worse, and how to manage it effectively.

Read More →

GLP‑1 and fatigue: why you feel tired and what helps

Fatigue affects about 11 percent of semaglutide users in clinical trials and is often linked to reduced calorie intake, dehydration, or protein deficiency. Learn why it happens and how to manage it.

Read More →

Next-generation weight loss medications: retatrutide, CagriSema, and what is coming in 2027

Several next-generation obesity medications are approaching FDA decisions, including retatrutide with 28.7 percent weight loss in Phase 3 and CagriSema with 22.7 percent. Here is what the pipeline looks like heading into 2027.

Read More →

Why protein matters on GLP‑1 medications: and how much you really need

Protein intake is crucial when taking semaglutide or tirzepatide. Learn why it helps preserve muscle, how much to aim for, and simple ways to hit your targets even when appetite is low.

Read More →

How long does a GLP‑1 stay in your system: half-life and washout explained

Semaglutide and tirzepatide stay in your body for weeks after a dose. Here is how half-life affects missed doses, surgery, switching, and side effects.

Read More →

Overview of GLP‑1 side effects: what to expect and how to manage them

GLP‑1 medications can cause digestive side effects, especially early on. Learn what's normal, when symptoms typically appear, and how to reduce discomfort as your body adjusts.

Read More →

Mastering injection site rotation: keep your GLP‑1 shots safe and comfortable

Repeatedly injecting in the same area can cause irritation and reduce absorption. Learn why rotating your injection sites matters, how to do it safely, and how Shotsy makes it effortless to track.

Read More →

Why tracking your GLP‑1 journey matters: benefits backed by data

Tracking your GLP‑1 experience helps improve medication adherence, reduce side effects, and understand long-term progress. Learn how data-driven habits can support better outcomes and how Shotsy makes it simple.

Read More →

Why GLP‑1 users need a new kind of health tracking app

Generic nutrition and fitness trackers are not designed for weekly injections, daily GLP‑1 pills, or the unique side effects of GLP‑1 medications. Learn why a dedicated app like Shotsy can simplify your routine, help you understand how your medication levels fluctuate and keep your progress on track.

Read More →